Achondroplasia is driven by overactive FGFR3 signaling that disrupts normal growth plate function. The panel explains how this molecular pathway affects endochondral bone growth and provides the foundation for understanding targeted treatment.
Back
Advancing Care in Achondroplasia: From Diagnosis to Clinical Evidence and Patient-Centered Care
A pediatric endocrinologist, a complex care pediatrician, and a clinical geneticist trace achondroplasia from its FGFR3 origins through diagnosis and skeletal and airway complications to the growing menu of CNP-pathway and investigational therapies, closing with guidance on monitoring, care coordination, and the patient advocacy organizations that support families long-term.
Advancing Care in Achondroplasia: From Diagnosis to Clinical Evidence and Patient-Centered Care
Episodes
All
All
Characteristic clinical and radiographic findings can establish early suspicion for achondroplasia, while molecular and prenatal testing are helping clinicians confirm the diagnosis sooner.
Beyond short stature, achondroplasia carries life-threatening risks at the skull base. The panel details why foramen magnum stenosis, hydrocephalus, and airway obstruction demand vigilant monitoring from infancy onward.
Height alone does not capture the full impact of achondroplasia. The panel discusses why health, function, proportionality, and independence are increasingly important measures of treatment success.
Earlier intervention may offer opportunities to influence skeletal development, but treatment timing must be weighed against uncertainty, treatment burden, and the needs of individual families.
Long-term data provide insight into sustained growth, proportionality, and safety across different pediatric age groups receiving CNP analogue therapy.
Once-weekly navepegritide provides sustained CNP exposure, with pivotal and longer-term data evaluating growth, skeletal alignment, physical function, and tolerability.
Investigational oral therapies are targeting the overactive FGFR3 pathway more directly, expanding the range of approaches under study for achondroplasia.
Response to growth-modulating therapy may evolve over several years. Structured monitoring helps clinicians assess benefit, manage expectations, and adapt treatment and orthopedic care when needed.
Long-term achondroplasia care extends beyond medical treatment to supporting independence, well-being, and connection throughout the patient journey.
Effective achondroplasia care depends on timely coordination across specialties, whether patients are managed at a dedicated multidisciplinary center or in the community.
Advertisement
Advertisement
Trending on HCPLive
1
Nalbuphine ER Rapidly Eases IPF Cough Burden, With Phil Molyneaux, MD, PhD
2
ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know
3
Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis
4
Sarcoidosis Care Starts With Inflammation vs Fibrosis: Rohit Gupta, MD
5